Anti-tumor necrosis factor therapies

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Long-term use of biologicals targeting tumor necrosis factor-alpha (TNF-alpha) has shown sustained improvement in rheumatoid arthritis (RA) symptoms.
• Efficacy and low immunogenicity are key criteria for successful anti-TNF agents in RA therapy.

Purpose of the Study:

• To evaluate the efficacy of current anti-TNF therapies in rheumatoid arthritis (RA).
• To assess the impact of anti-TNF agents on joint structural damage and disability in RA patients.

Main Methods:

• Review of published studies on infliximab and etanercept regimens for RA.
• Analysis of 1-year data for infliximab and methotrexate combination therapy.
• Evaluation of etanercept's efficacy in early RA compared to methotrexate.

Main Results:

• Infliximab (3 or 10 mg/kg) with methotrexate, and etanercept (25 mg twice weekly) appear to be efficacious and of low immunogenicity.
• Anti-TNF therapy has demonstrated protection of joints from structural damage.
• Combination therapy with infliximab and methotrexate reduced disability in RA patients over 1 year.
• Etanercept showed faster symptom reduction and erosion progression retardation in early RA compared to methotrexate.

Conclusions:

• Anti-TNF therapies, including infliximab and etanercept, establish a new standard for symptom control in both established and early RA.
• These biological agents provide significant joint protection, mitigating structural damage progression.
• The combination of anti-TNF agents with methotrexate offers sustained benefits and reduced disability in RA management.